UBS Group’s Entera Bio ENTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.56K | Buy |
3,212
+3,195
| +18,794% | +$4.48K | ﹤0.01% | 9065 |
|
|
2025
Q4 | $33 | Sell |
17
-10,435
| -100% | -$24.5K | ﹤0.01% | 10308 |
|
|
2025
Q3 | $20.1K | Sell |
10,452
-5,179
| -33% | -$9.91K | ﹤0.01% | 8149 |
|
|
2025
Q2 | $29.7K | Buy |
+15,631
| New | +$30.9K | ﹤0.01% | 8167 |
|
|
2024
Q4 | – | Sell |
-142,747
| Closed | -$271K | – | 10045 |
|
|
2024
Q3 | $271K | Sell |
142,747
-24,876
| -15% | -$44.1K | ﹤0.01% | 5650 |
|
|
2024
Q2 | $308K | Buy |
167,623
+17,754
| +12% | +$38.9K | ﹤0.01% | 5378 |
|
|
2024
Q1 | $250K | Buy |
+149,869
| New | +$165K | ﹤0.01% | 5698 |
|
|
2023
Q4 | – | Sell |
-614
| Closed | -$445 | – | 9453 |
|
|
2023
Q3 | $445 | Sell |
614
-450
| -42% | -$331 | ﹤0.01% | 8490 |
|
|
2023
Q2 | $897 | Sell |
1,064
-8,676
| -89% | -$7.41K | ﹤0.01% | 8069 |
|
|
2023
Q1 | $11.3K | Sell |
9,740
-648
| -6% | -$647 | ﹤0.01% | 7518 |
|
|
2022
Q4 | $7.58K | Buy |
10,388
+8,634
| +492% | +$6.25K | ﹤0.01% | 8885 |
|
|
2022
Q3 | $2K | Sell |
1,754
-5,650
| -76% | -$8.53K | ﹤0.01% | 9714 |
|
|
2022
Q2 | $10K | Buy |
7,404
+2,744
| +59% | +$6.1K | ﹤0.01% | 7953 |
|
|
2022
Q1 | $13K | Buy |
+4,660
| New | +$11.2K | ﹤0.01% | 8042 |
|
|
2021
Q4 | – | Sell |
-565
| Closed | -$3K | – | 10358 |
|
|
2021
Q3 | $3K | Sell |
565
-457
| -45% | -$2.34K | ﹤0.01% | 8803 |
|
|
2021
Q2 | $6K | Sell |
1,022
-592
| -37% | -$2.19K | ﹤0.01% | 8435 |
|
|
2021
Q1 | $6K | Buy |
1,614
+1,144
| +243% | +$2.63K | ﹤0.01% | 8229 |
|
|
2020
Q4 | $1K | Sell |
470
-7,368
| -94% | -$8.14K | ﹤0.01% | 8210 |
|
|
2020
Q3 | $10K | Sell |
7,838
-2,544
| -25% | -$3.86K | ﹤0.01% | 6840 |
|
|
2020
Q2 | $19K | Buy |
+10,382
| New | +$21.2K | ﹤0.01% | 6584 |
|
|
2020
Q1 | – | Sell |
-620
| Closed | -$1K | – | 8061 |
|
|
2019
Q4 | $1K | Buy |
620
+155
| +33% | +$355 | ﹤0.01% | 7935 |
|
|
2019
Q3 | $1K | Sell |
465
-222
| -32% | -$633 | ﹤0.01% | 7827 |
|
|
2019
Q2 | $2K | Sell |
687
-450
| -40% | -$1.75K | ﹤0.01% | 7612 |
|
|
2019
Q1 | $5K | Buy |
+1,137
| New | +$4.6K | ﹤0.01% | 7156 |
|
|
2018
Q4 | – | Sell |
-365
| Closed | -$2K | – | 8096 |
|
|
2018
Q3 | $2K | Sell |
365
-1,074
| -75% | -$5.89K | ﹤0.01% | 7734 |
|
|
2018
Q2 | $9K | Buy |
+1,439
| New | +$9.05K | ﹤0.01% | 7186 |
|
Other funds holding ENTX
KCM
PHP
SFCM
XT
SSA
SEIA
UBS Group's ENTX Position: Q1 2026 in Review
UBS Group increased its Entera Bio (ENTX) stake by 18,794% in Q1 2026, buying an estimated $4.48K and bringing the position to 3,212 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #9065.
UBS Group first reported a position in ENTX in Q2 2018 and has held it in 26 quarters since. The position peaked at $308K in Q2 2024. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.
- UBS Group held 3,212 shares of Entera Bio worth $3.56K as of Q1 2026.
- UBS Group bought 3,195 Entera Bio shares in Q1 2026, an estimated $4.48K.
- Entera Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9065 holding.
- UBS Group first reported a position in Entera Bio in Q2 2018 and has held it in 26 quarters since.
- UBS Group's Entera Bio position peaked at $308K in Q2 2024.
- 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.